Recent studies have shown that the prevalence of hypertension and prehypertension has markedly increased among children and adolescents, highlighting the importance of identifying the mechanisms underlying the elevated BP in early life. 2 Accumulating evidence shows that fetal programming plays a significant role in adult hypertension. Low birth weight (LBW) may influence the rate of weight gain during childhood, body weight in adults, and BP during childhood and adulthood.
A rterial hypertension is a risk factor for kidney, cerebrovascular, and coronary heart diseases and affects about one-third of the adult population in Western societies. 1 Blood pressure (BP) regulation is an integrated complex response involving various organ systems, including the vasculature, heart, kidneys, adrenal glands, and the central nervous system. 1 to the vascular changes causing eventual hypertension remain largely unknown. This is due, at least in part, to the lack of appropriate animal models.
RGC-32 (response gene to complement 32) was first cloned from rat oligodendrocytes responding to complement activation. 9 RGC-32 is expressed in several organs or tissues such as placenta, kidney, brain, liver, heart, adipose tissue, vascular smooth muscle cells (VSMCs), endothelial cells, macrophages, and T cells. [10] [11] [12] [13] [14] [15] [16] Functionally, RGC-32 regulates cell proliferation, differentiation, epithelial-mesenchymal transition, and fibroblast activation. 10, 12, 16, 17 Our previous studies have shown that RGC-32 deficiency (RGC-32 −/− ) in mice causes fetal growth restriction by interrupting placental angiogenesis, resulting in a lower birth weight followed by accelerated weight gain during the first 4 weeks of life. 18 Therefore, we undertook the current study to test the hypothesis that BP is elevated in RGC-32 −/− mice. We found that RGC-32 −/− mice did exhibit higher BP than WT (wild type) mice. Therefore, −/− mice may serve as a valuable animal model for studying the mechanisms underlying hypertension associated with LBW and rapid early childhood weight gain.
In the current study, we also found that the increased BP observed in −/− mice is associated with increased vascular tone and an increase in the relative influence of sympathetic versus parasympathetic activity on cardiovascular function. Our additional finding that RGC-32 deficiency is associated with increased expression of AT1R (Ang II [angiotensin II] type I receptor) and α1-AdR (α1-adrenergic receptor) in arterial VSMCs led us to postulate a causal link between these events, that is, that RGC-32 may normally modulate α1-AdR levels by inhibiting AT1R expression. Our results showed that RGC-32 inhibits AT1R gene transcription by interacting with Sp1 (specificity protein 1), thus blocking its binding to AT1R promoter and attenuating AT1R expression. Decreased AT1R expression, in turn, inhibits α1-AdR expression.
Methods
The authors declare that all methods and supporting data are available within the article and its Online Data Supplement.
Animals
Male RGC-32 −/− mice in C57BL6 genetic background and the genotyping primers and procedures have been described previously. 18 Only male mice were included in this study because sex differences are observed in the pathophysiological response to an adverse fetal environment and in fetal programming of hypertension in both mouse and human. 19 Thus, female mice need to be studied separately. Experiments were performed on 3-to 6-month-old male C57BL6 and RGC-32 −/− mice, and animals were assigned using a simple randomization method. All animal experiments were completed within 2 years. The data collection and analyses were conducted in a doubleblinded manner. Mice were housed in a conventional environment with a 12-hour light/dark cycle and allowed free access to water and chow diet. All animal procedures were performed according 
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Novelty and Significance
What Is Known?
• Hypertension is more prevalent among children and adolescents with low birth weight (LBW).
• Fetal programming plays a significant role in adult hypertension.
• RGC-32 (response gene to complement 32) deficiency in mice causes fetal growth restriction by interrupting placental angiogenesis.
What New Information Does This Article Contribute?
• RGC-32 deficiency causes LBW and high blood pressure (BP) in adult mice.
• RGC-32 regulates BP homeostasis by altering vascular tone and distensibility of small resistance arteries.
• RGC-32 modulates α1-AdR (α1-adrenergic receptor) level by inhibiting AT1R (angiotensin II type I receptor) expression.
Previous studies have shown that LBW influences the rate of weight gain during childhood and BP during childhood and adulthood. However, the underlying mechanisms by which LBW and rapid early childhood weight gain lead to vascular changes causing eventual hypertension remain largely unknown. This is due, in part, to the lack of appropriate animal models. Here, we use an RGC-32-deficient mouse model to identify the mechanism underlying the LBW-related hypertension. Our studies show that RGC-32 is a novel protein factor vital for maintaining BP homeostasis, especially in individuals with LBW. RGC-32 regulates BP by maintaining vascular tone and distensibility of small resistance arteries. RGC-32 deficiency increases vascular tone by enhancing the relative contribution of sympathetic versus parasympathetic activity and the expression of AT1R and α1-AdR in arterial smooth muscles. In the molecular level, RGC-32 regulates AT1R gene transcription by interacting with transcription factor Sp1 (specificity protein 1) and further blocking its binding to AT1R promoter, leading to suppression of AT1R expression. Decrease in AT1R expression causes downregulation of α1-AdR, which leads to balanced control of vascular tone.
Human Samples
The study was performed by strictly following international ethical guidelines for biomedical research involving human subjects published by CIOMS (Council for International Organizations of Medical Sciences) and was approved by the Institutional Review Board of Shiyan Renmin Hospital, Hubei University of Medicine. Written informed consent was obtained from all participating individuals. Human umbilical cords were collected before disposal after babies were born in Shiyan Renmin Hospital. The thoracic aorta specimens were collected during the postmortem examination with informed consent from patients or family members.
Reagents and Chemicals
Phenylephrine (P616), atropine (A0132), prazosin (A7791), hexamethonium (H2138), Ang II (A9525), norepinephrine (NE; A0937), sodium nitroprusside (71778), azilsartan (SML0432), and propranolol (P8688) were purchased from Sigma-Aldrich and reconstituted in their corresponding vehicle according to the manufacturer's instructions. RSV-Sp1 plasmid was obtained from Addgene.com (plasmid No. 12098).
BP Measurements
BP in conscious, unrestrained male mice (n=6 each; WT and RGC-32
) was measured using a radiotelemetry system (Data Science International), as described previously. 20 To measure acute responses to various substances, BP and heart rate (HR) were collected continuously in 5-second intervals, and the values were averaged over an interval of 1 minute after a 10-minute recovery after injection of each substance. The following drugs were administered as single intraperitoneal injections: atropine (1 mg/kg IP), propranolol (1 mg/kg IP), prazosin (1 mg/kg IP), phenylephrine (1 mg/kg IP), hexamethonium (20 mg/kg IP), and azilsartan (3.2 mg/kg IP), with a 48-hour washout period allowed between administration of each substance.
20,21
Vessel Distensibility and Vascular Tone Measurement
To measure vascular distensibility, the second-order branches of the mesenteric resistance artery (MRA) 22 from 5 to 8 mice of each genotype were isolated and mounted onto the glass cannulae in the chamber of Culture Myograph System (DMT). The vessel wall thickness, passive inner, and outer diameters over a range of intralumenal pressures (0-160 mm Hg) was measured as described previously. 23 Distensibility (D20) was defined as percentage change in luminal volume per mm Hg during stepwise changes in intravascular pressure, as described previously. 24 Myogenic reactivity was measured over a pressure range of 10 to 160 mm Hg in both Ca 2+ -containing PSS (physiological salt solution, active tone) and Ca 2+ -free PSS (passive tone). Vascular tone and myogenic index were calculated as described previously. M) was measured by recording the lumen diameter change in pressurized (70 mm Hg) MRA and was calculated as described previously. 22 The relative vessel resistance per unit length was calculated as described previously. , respectively. These dosage rates have been shown to induce modest systolic arterial hypertension. 27, 28 Saline-infused mice served as controls. Indirect BPs were measured with a noninvasive computerized tail-cuff system (CODA-MNTR, KENT), as described previously, at baseline and after 14 days of infusion.
29
Histomorphometric Analysis, Immunohistochemistry, and Immunofluorescent Staining
Elastin contents of MRAs from 3-month-old mice were analyzed as described previously. 23 α-SMA (α-smooth muscle actin) expression or myosin light chain phosphorylation in MRA, calponin expression in kidney artery, or RGC-32 expression in human umbilical arteries (UAs) or aorta specimens were examined by immunohistochemistry or immunofluorescent as described previously.
14,16
Whole-Mount Double Staining of Retinal Vessels
Mouse retinas were obtained and labeled with anti-α-SMA-Cy3 (5 µg/mL; C6198; Sigma-Aldrich) and lectin-fluorescein isothiocyanate (5 µg/mL; L2895; Sigma-Aldrich) antibodies as described previously. 30 The diameter of each vessel was measured using the Nikon Elements software. Retinal arteriole-to-venule diameter ratios were calculated and averaged for each image.
Quantitative Reverse Transcription Polymerase Chain Reaction
Total RNA was extracted from arteries or kidneys of 3-month-old RGC-32 −/− mice and WT control littermates using TRIzol reagents (Life Technologies). Transcript levels of genes of interest in WT and RGC-32 −/− kidneys were analyzed by quantitative polymerase chain reaction and compared after normalization to cyclophilin levels as described previously. 12 The primers used are listed in Online Table I .
Western Blot
Mouse MRA, human UA, or rat primary aortic VSMCs were homogenized on ice in 0.1% Tween-20 homogenization buffer containing protease inhibitors. Western blot was performed as described previously. 17 Primary antibodies used were goat anti-AT1R (ab59018; Abcam), rabbit anti-α1A-AR (ab137123; Abcam), rabbit anti-α1B-AR (ab169523; Abcam), rabbit anti-α1D-AR antibody (ab84402; Abcam), α-tubulin (T9026; Sigma), and RGC-32, 17 respectively.
Determination of Plasma Catecholamines
Plasma concentrations of epinephrine and NE were determined by ELISA (CatCombi; IBL, Hamburg) as described previously. 21 To keep the sampling conditions consistent for all animals, extreme care was taken when collecting the samples. Blood samples were taken by submandibular bleeding within 10 seconds of capture of the mouse.
Promoter Reporter Luciferase Assay
Primary rat VSMCs were transduced with adenoviral vectors expressing GFP or RGC-32 and transfected with AT1R promoter construct for 48 hours followed by vehicle or Ang II treatment (200 nmol/L) for 24 hours. Luciferase assay was performed using the Dual-Luciferase Reporter Assay System (Promega). 31 Independent experiments were performed in triplicate and repeated for 3×.
Coimmunoprecipitation Assay
Cells were lysed with ice-cold mild lysis buffer containing protease inhibitor mix provided in a Co-Immunoprecipitation Kit (Thermo Scientific). The lysates were incubated with IgG (negative control), Sp1, or RGC-32 antibodies. The immunoprecipitates were pelleted, washed, and subjected to immunoblotting according to the manufacturer's instructions.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation assays were performed using a Chromatin Immunoprecipitation Kit (Millipore). 32 Growth-arrested primary rat VSMCs were treated with Ang II for 24 hours. Chromatin complexes were immunoprecipitated with 3 μg of Sp1 antibody or IgG (negative control) according to the manufacturer's instructions. Semiquantitative polymerase chain reaction and quantitative polymerase chain reaction were performed to amplify the AT1R promoter region containing GC box sequence (Sp1-binding site) using the following primer set: 5′-AGC TGA GCT TGG ATC TGG AA-3′ (forward) and 5′-GAG GTC AGC AGC TAG GCA CT-3′ (reverse).
Statistical Analysis
All values are presented as mean±SEM. All data were evaluated for normality by D'Agostino-Pearson Omnibus test. For data with a normal distribution, statistical difference was calculated by the Student t test or 1-way ANOVA. The Bonferroni multiple comparisons test was used after the 2-way ANOVA for post hoc analysis. For data that were not normally distributed, the Mann-Whitney U test was used. Two-sided P <0.05 was considered as statistically significant. All statistical analyses were performed using Prism software (GraphPad Software, Inc; InStat, version 3.06).
Results
RGC-32 −/− Mice Exhibited Elevated BP
RGC-32 −/− mice had LBW compared with their WT littermates. However, at 5 weeks of age, no body weight difference was observed between the WT and RGC-32 −/− mice, suggesting a greater rate of weight gain in RGC-32 −/− mice during the immediate postnatal period. 18 Because of this difference in growth rate, we measured BP at 3 to 6 months of age in both strains. Mean arterial pressure was significantly greater in RGC-32 −/− mice compared with WT littermates (101±4 versus 119±5 mm Hg), as measured by radiotelemetry ( Figure 1A and 1B), which allowed the measurement of BP and HRs during a 24-hour period. The higher values for mean arterial pressure and HRs were particularly pronounced during the awake hours in RGC-32 −/− mice ( Figure 1A through 1D ). Generalized narrowing of arterioles in the retina has been found in lower birth weight children and is recognized as an early characteristic of hypertension in adulthood. 4, 5, 33 In the normal retina, the ratio of arteriolar diameter to venular diameter is typically 2:3, and myogenic constriction of retinal arterioles in response to the increased BP results in a reduction of this ratio. 34 Thus, determining relative changes in the size of small vessels of the retina is an effective way to monitor the in vivo response of these vessels to high BP. As shown in Figure 1E , the loss of RGC-32 was associated with a significant decrease in the retinal arteriolar-to-venular diameter ratio (from 2:3 to 1:2; Figure 1F ). Consistent with this finding, retinal arteriolar diameters in RGC-32 −/− mice were reduced by 12.7%, as compared with those in WT mice. Moreover, analysis of cardiac hypertrophy-an adaptive response to a pressure-dependent increase in mechanical load of cardiomyocytes-revealed an increase in left ventricle-to-body weight ratios in RGC-32 −/− mice (Online Figure IA) . Notably, although no obvious difference for left ventricle-to-body weight ratios was observed between 3-and 6-month-old RGC-32 −/− mice, the BP was further increased in 6-versus 3-month-old RGC-32 −/− mice (Online Figure IB) , suggesting that a cardioprotective mechanism might be present to prevent the left ventricle from further damage in these mice. These results indicate that RGC-32 deficiency is associated with a significant increase in systemic arterial BP and the related complications, such as cardiac hypertrophy and retinal arteriolar constriction.
RGC-32 Deficiency Decreased Vascular Distensibility and Increased Responsiveness to Vasoconstrictor Stimuli
Small arteries and arterioles are the main determinants of peripheral resistance and thus play a central role in BP homeostasis. 35 We thus analyzed passive mechanical characteristics and active responsiveness to vasoconstrictor stimuli in MRA under defined pressures. As shown in Figure 2A and 2B, the passive diameter of RGC-32 −/− MRA was smaller than that of WT MRA. For each applied pressure, the passive diameter of RGC-32 −/− MRA was also smaller ( Figure 2B ), leading to an increased wall thickness-to-lumen ratio compared with the WT controls at most pressures ( Figure 2C ). Moreover, compared with the WT MRA, MRA from RGC-32 −/− mice showed significantly higher relative resistances and significantly lower distensibilities over the range of intraluminal pressures tested ( Figure 2D and 2E). Similar differences between groups were observed when MRAs were exposed to buffer containing Ca 2+ (Online Figure II) . Furthermore, the To further characterize the effect of RGC-32 deficiency on smooth muscle contractility in MRA, we applied the depolarization agent KCl and vessel constrictor NE to the WT and RGC-32 −/− MRA under 70 mm Hg intraluminal pressures. As shown in Figure 2G and 2H, RGC-32 −/− MRA responses to KCl or NE stimulation were greater than those of WT MRA, as shown by the increased vessel contraction. These data suggest that RGC-32 −/− mice developed high BP due, at least in part, to the increased responsiveness of small resistance arteries to vasoconstrictor stimuli.
RGC-32 Regulated BP Through Effects on the α-AdR
Sympathetic regulation of cardiac function and vascular tone is central to BP homeostasis and tissue perfusion, and an increase in the relative influence of the sympathetic versus parasympathetic systems on cardiovascular function can contribute to the pathogenesis of hypertension. 36 Therefore, we tested whether RGC-32 deficiency causes sympathetic-parasympathetic imbalance, or dysautonomia, in conscious mice. The increase in HR observed after the administration of atropine in WT mice was significantly attenuated in RGC-32 −/− mice ( Figure 3A and 3B), indicating less parasympathetic contribution to resting HR in the latter. Conversely, the decrease in HR in response to propranolol administration in RGC-32 −/− mice was >2-fold greater than in WT mice ( Figure 3C and 3D The new BP levels were attained within minutes, indicating that chronic volume retention was unlikely to be a major pathogenic factor in the maintenance of hypertension in RGC-32 −/− mice. Increased sympathetic nerve activity often leads to increased systemic catecholamine levels. 20 Therefore, we measured plasma epinephrine and NE levels in both WT and RGC-32 −/− mice. RGC-32 deficiency was not associated with significantly altered plasma epinephrine or NE, compared with WT controls ( Figure 4A ). Because sympathetic nerves regulate vascular tone through binding of the neurotransmitter NE to α-AdR (α-adrenergic receptor) in arterial VSMCs, 10, 35 we measured the expression of both the α1-and α2-AdR (α2-adrenergic receptor) in MRA. As shown in Figure 4B , RGC-32 deficiency was associated with a significant increase in mRNA transcript levels of all α1-AdR but not every α2-AdR. RGC-32 deficiency also increased the protein expression of α1-AdR by ≈1.8-fold ( Figure 4C and 4D), suggesting that RGC-32 deficiency may enhance the sensitivity of resistance arteries to sympathetic nerve activity by increasing α1-AdR density. Indeed, RGC-32 −/− mice exhibited a greater BP response to phenylephrine stimulation (61.8±6.6 versus 49.2±3.6 mm Hg; Figure 4E 
RGC-32 Regulated BP Through Effects on the AT1R
The renin-angiotensin-aldosterone system plays an important role in BP regulation. 21, 37 Although RGC-32 −/− mice exhibited slightly higher plasma and urine volumes associated with higher water intake (Online Figure VA through VD) , renal function of RGC-32 −/− mice appeared to be normal as shown by the normal hematocrit and fractional excretion of sodium, as well as the normal levels of plasma aldosterone, Na + , and K + (Online Figure VE through VH) , suggesting that RGC-32 deficiency caused the significant increase in BP through mechanisms independent of the alteration in kidney functions. However, the vasoconstrictor response to Ang II was greater in RGC-32 −/− mice, as shown by a larger increase in BP than in WT mice (39.3±3.1 versus 28.3±1.8 mm Hg; Figure 5A ). In addition, the AT1R inhibitor azilsartan caused a larger decrease in BP in RGC-32 −/− mice (41.1±1.6 versus 28.6±2.6 mm Hg; Figure 5B ). Furthermore, Ang II infusion by mini-pump caused a greater BP elevation in RGC-32 −/− mice (44.9±5.9 versus 37.0±2.0 mm Hg; Figure 5C ) and contributed to the further narrowing of retinal arterioles, resulting in a smaller retinal arteriolar-to-venular diameter ratio (2:5 versus 1:2; Online Figure IVC and IVD) . Renin expression was increased in the kidneys and arterial VSMC whereas AGT (angiotensinogen) and ACE1 (angiotensin-converting enzyme 1) mRNA levels were elevated in livers and lungs of RGC-32 −/− mice, respectively (Online Figure VI through VL) . These results further suggested that RGC-32 deficiency may be associated with augmentation of the RAS.
Because RGC-32 is expressed only in VSMC of kidney resistance arteries in the normal mouse kidney, 12 and VSMCs are the effector cells for vessel contraction, we determined whether RGC-32 deficiency affects the expression of Ang II receptors in MRA. As shown in Figure 5D , RGC-32 deficiency increased mRNA transcript levels for both AT1R and the AT2R (Ang II type 2 receptor). However, the increase in expression for the AT1R was much more dramatic than the AT2R. Indeed, RGC-32 deficiency also caused a significant increase (2.4-fold) in AT1R protein expression in MRA ( Figure 5E ). These data suggest that RGC-32 may confine AT1R expression in normal resistance arteries to maintain BP homeostasis.
Previous studies have shown that AT1R not only mediates the vasoconstrictor function of Ang II but also regulates α1-AdR expression in VSMCs. 38 Indeed, Ang II stimulation or overexpression of AT1R upregulated α1-AdR expression in VSMCs ( Figure 5F and 5G). RGC-32 overexpression, however, inhibited Ang II-induced α1-AdR expression, which was rescued by AT1R overexpression (Figure 5F and 5G). Because AT1R is negatively regulated by RGC-32 ( Figure 5D and 5E), RGC-32 may modulate α1-AdR levels by inhibiting AT1R expression.
RGC-32 Interacted With Sp1 and Blocked Sp1-Mediated AT1R Promoter Activity
To explore the mechanism by which RGC-32 restrains AT1R expression, we tested whether RGC-32 regulates AT1R promoter activity. As shown in Figure 6A , Ang II increased AT1R promoter activity. However, forced expression of RGC-32 significantly attenuated the Ang II-activated AT1R promoter activity, suggesting that RGC-32 is involved in AT1R gene transcription. Previous studies have shown that the transcription factor Sp1 plays a critical role in Ang II-induced AT1R gene transcription in VSMCs. 39 Indeed, Sp1 enhanced AT1R promoter activity in both basal and Ang II-induced states ( Figure 6B ). However, forced expression of RGC-32 significantly attenuated Sp1-and Ang II-mediated increases in AT1R promoter activity ( Figure 6B ), suggesting that Sp1 activity in AT1R transcription was regulated by RGC-32.
To determine how RGC-32 regulated Sp1 function, we tested whether RGC-32 physically interacts with Sp1. Coimmunoprecipitation assays showed that RGC-32 had a strong interaction with Sp1 in the basal VSMCs ( Figure 6C and 6D) because the protein complex pulled down by Sp1 antibody contained a high level of RGC-32. However, Ang II treatment caused a 2.4-fold reduction in RGC-32 interaction with Sp1, consistent with the higher BP in RGC-32 −/− , compared with WT, mice. RGC-32-Sp1 interaction was confirmed by a reverse coimmunoprecipitation using RGC-32 antibody to pull-down Sp1 ( Figure 6E and 6F) .
To further determine how RGC-32 regulates Sp1 activity, we tested whether RGC-32 affects Sp1 binding to AT1R promoter. Thus, we performed chromatin immunoprecipitation assay to detect the enrichment of Sp1 binding to AT1R promoter in a chromatin setting. As shown in Figure 6G and 6H, Sp1 bound to the AT1R promoter, and Ang II treatment enhanced the binding by 2.3-fold. However, forced expression of RGC-32 diminished the Sp1 binding ( Figure 6G and 6H) , demonstrating that RGC-32 inhibited AT1R gene transcription by blocking Sp1 binding to AT1R promoter. Collectively, our results suggest that RGC-32 deficiency promotes Sp1 activity in AT1R expression, leading to an enhanced AT1R level in VSMC and thus a disruption of normal vascular tone.
RGC-32 Reduction Was Associated With LBW and Hypertension in Human
To determine whether RGC-32 deficiency-caused LBW and hypertension in mice is relevant to human conditions, we collected UA of human individuals with LBW and normal birth weights. Because UA originates from internal iliac artery of the fetus, these arteries are ideal to observe the potential association between RGC-32 level and birth weight in humans. As shown in Figure 7A through 7C, RGC-32 was abundantly expressed in UA media layer, especially in α-SMA-positive VSMCs from individuals with normal birth weight, but its expression level was reduced by 10-fold in UA media VSMCs from individuals with LBW, suggesting that RGC-32 reduction is indeed associated with LBW in humans. Moreover, although RGC-32 was expressed at a low level in aortic media of human individuals with normal BP, its expression was dramatically reduced in aortic media of hypertensive patients ( Figure 7D and 7E). These data indicated that RGC-32 deficiency is associated with both LBW and hypertension in humans.
Discussion
In the present study, we have identified RGC-32 as a novel factor important for BP homeostasis. RGC-32 deficiency disrupts normal BP homeostasis, leading to significant increases in systemic arterial pressure. Because RGC-32 −/− mice exhibit LBW with an accelerated growth rate in later life to gain normal adult weight while developing hypertension, RGC-32 deficiency may be an essential factor causing LBW-related hypertension. Thus, RGC-32 −/− mice may serve as a valuable model for dissecting molecular mechanisms underlying LBW-related hypertension. Indeed, we have identified a novel mechanism underlying LBW-linked hypertension; that is, increased vascular tone because of increased expression of AT1R and α1-AdR in VSMC by RGC-32 deficiency. The elevated α1-AdR in VSMC, coupled with the exaggerated sympathetic control of the cardiovascular system, further disrupts the BP homeostasis.
RGC-32 appears to inhibit α1-AdR expression in VSMCs by regulating AT1R gene transcription. RGC-32 inhibits AT1R promoter activity, which explains the increased AT1R expression observed in RGC-32 −/− VSMCs. RGC-32 mitigates AT1R transcription not by directly binding to AT1R promoter but by inhibiting the activity of key transcription factor Sp1. RGC-32 physically interacts with Sp1 to limit its binding to AT1R promoter, resulting in the controlled AT1R levels.
Interestingly, 6-month-old RGC-32 −/− mice exhibit an increased BP with similar left ventricle weight as compared with 3-month-old RGC-32 −/− mice. Previous studies using an elegant intrauterine growth restriction rat model show that male intrauterine growth restriction offspring remains hypertensive in adulthood largely because of testosterone with the participation of the RAS. 40, 41 The augmented RAS in male RGC-32 −/− mice is consistent with the inverse relationship between birth weight and BP in the intrauterine growth restriction rat model. 40 The increase in BP without exacerbation in left ventricle hypertrophy in 6-versus 3-month-old RGC-32 −/− mice is likely because of the function of testosterone as testosterone is reported to protect the heart from hypertrophy or remodeling. 42, 43 However, extensive studies would be required to clearly establish the potential diverse roles of testosterone in the hypertension and cardiac hypertrophy observed in RGC-32 −/− mice. Although the kidney is critical in BP regulation, RGC-32 deficiency does not alter renal function. Our previous study shows that RGC-32 knockdown protects the kidney from ureter obstruction-induced renal fibrosis although the pathological processes, as well as the mechanism underlying this Figure VI) , consistent with the increased vascular tone in RGC-32 −/− MRA. Because both renal artery and MRA are small arteries, they may undergo similar pathological alterations when RGC-32 is deleted. Therefore, lack of RGC-32 in resistance artery VSMCs may be the major factor causing increased vascular tone and hypertension in RGC-32 −/− mice. In addition, because RGC-32 deletion increases renin expression in kidney and VSMCs along with increased AGT expression in liver and ACE1 in lung, it is likely that the circulating Ang II level is elevated, which may contribute to the increased vascular tone. Moreover, renal nerve activity is known to play an important role in mediating LBWlinked hypertension, 44 RGC-32 may maintain BP homeostasis also by regulating the renal sympathetic nerve activity, which may be studied in the future.
Of importance, RGC-32 deficiency is related to LBW and hypertension in humans. RGC-32 is abundantly expressed in arterial medial VSMCs of UA of fetuses who are born with normal weights. However, RGC-32 levels are significantly reduced in arteries of fetus with LBW. These data are consistent with previous studies showing the RGC-32 is significantly downregulated in human preeclamptic placentas compared with normal controls. 45, 46 Preeclampsia is known to be a major contributor to preterm and LBW babies in humans. 47 Furthermore, RGC-32 is also downregulated in human hypertensive subjects, suggesting that restoring RGC-32 expression may be a potential effective strategy for treating preeclampsia or LBW-associated complications, including hypertension.
Taken together, our current findings suggest that RGC-32 deficiency disrupts BP homeostasis through multiple mechanisms, specifically by augmenting the RAS, increasing vascular tone, and interrupting the balance between sympathetic and parasympathetic influences on cardiovascular function (Online Figure VII) . Whether ≥1 of these mechanisms play a dominant role requires future investigation. Nevertheless, RGC-32 −/− mice may be a valuable model for studying LBWrelated hypertension, and our results reveal a novel mechanism underlying this pathological process.
Sources of Funding
This study was supported by grants from the National Institutes of Health (HL119053, HL123302, and HL135854 to S.-Y. Chen), the National Natural Science Foundation of China (81670272 to 
